Allergen Immunotherapy: Current and Future Trends release_xr3czkdlwbairmol2wnlztb62y

by Gandhi F. Pavón-Romero, Maria Itzel Parra-Vargas, Fernando Ramírez-Jiménez, Esmeralda Melgoza-Ruiz, Nancy H. Serrano-Pérez, Luis Manuel Teran

Published in Cells by MDPI AG.

2022   Volume 11, Issue 2, p212

Abstract

Allergen immunotherapy (AIT) is the sole disease-modifying treatment for allergic rhinitis; it prevents rhinitis from progressing to asthma and lowers medication use. AIT against mites, insect venom, and certain kinds of pollen is effective. The mechanism of action of AIT is based on inducing immunological tolerance characterized by increased IL-10, TGF-β, and IgG4 levels and Treg cell counts. However, AIT requires prolonged schemes of administration and is sometimes associated with adverse reactions. Over the last decade, novel forms of AIT have been developed, focused on better allergen identification, structural modifications to preserve epitopes for B or T cells, post-traductional alteration through chemical processes, and the addition of adjuvants. These modified allergens induce clinical-immunological effects similar to those mentioned above, increasing the tolerance to other related allergens but with fewer side effects. Clinical studies have shown that molecular AIT is efficient in treating grass and birch allergies. This article reviews the possibility of a new AIT to improve the treatment of allergic illness.
In application/xml+jats format

Archived Files and Locations

application/pdf  2.2 MB
file_wxalm7uth5c5zcgj4emxt75ed4
mdpi-res.com (web)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2022-01-08
Language   en ?
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  2073-4409
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: aed78cd9-c100-460e-ab10-8d8e8f9c578d
API URL: JSON